カテゴリー： 世界, 医療/バイオ, Market Monitor Global

世界のリファマイシン市場予測2023-2029：タブレット、カプセル

【英語タイトル】Rifamycin Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料（MMG23LY8640）・商品コード：MMG23LY8640
・発行会社（調査会社）：Market Monitor Global
・発行日：2023年7月
・ページ数：119
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界のリファマイシン市場規模と予測を収録しています。・世界のリファマイシン市場：売上、2018年-2023年、2024年-2029年
・世界のリファマイシン市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のリファマイシン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「タブレット」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

リファマイシンのグローバル主要企業は、Merck、 Labcorp Drug Development、 Mylan、 Sandoz、 Sanofi Pharmaceuticals、 AdvaCare Pharma、 EUROAPI、 Lupin Ltd、 Olon S.p.A、 CKD Bio Corporation、 Fermic、 Sichuan Long March Pharmaceutical Co. Ltd.、 Novartis Pharmaceuticals Corporation、 Hanways Chempharm Co., Limited、 Otto Brandes、 Arudavis Labs、 Zhengzhou Minzhong Pharmaceutical Co., Ltd、 Lannett、 Acme Pharmaceuticals、 Macleods Pharmaceuticals Ltd.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、リファマイシンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のリファマイシン市場：タイプ別、2018年-2023年、2024年-2029年
世界のリファマイシン市場：タイプ別市場シェア、2022年
・タブレット、カプセル

世界のリファマイシン市場：用途別、2018年-2023年、2024年-2029年
世界のリファマイシン市場：用途別市場シェア、2022年
・薬局、病院、診療所、その他

世界のリファマイシン市場：地域・国別、2018年-2023年、2024年-2029年
世界のリファマイシン市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるリファマイシンのグローバル売上、2018年-2023年
・主要企業におけるリファマイシンのグローバル売上シェア、2022年
・主要企業におけるリファマイシンのグローバル販売量、2018年-2023年
・主要企業におけるリファマイシンのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Merck、 Labcorp Drug Development、 Mylan、 Sandoz、 Sanofi Pharmaceuticals、 AdvaCare Pharma、 EUROAPI、 Lupin Ltd、 Olon S.p.A、 CKD Bio Corporation、 Fermic、 Sichuan Long March Pharmaceutical Co. Ltd.、 Novartis Pharmaceuticals Corporation、 Hanways Chempharm Co., Limited、 Otto Brandes、 Arudavis Labs、 Zhengzhou Minzhong Pharmaceutical Co., Ltd、 Lannett、 Acme Pharmaceuticals、 Macleods Pharmaceuticals Ltd.

*************************************************************

・調査・分析レポートの概要
リファマイシン市場の定義
市場セグメント
世界のリファマイシン市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のリファマイシン市場規模
世界のリファマイシン市場規模：2022年 VS 2029年
世界のリファマイシン市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのリファマイシンの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のリファマイシン製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：タブレット、カプセル
リファマイシンのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：薬局、病院、診療所、その他
リファマイシンの用途別グローバル売上・予測

・地域別市場分析
地域別リファマイシン市場規模 2022年と2029年
地域別リファマイシン売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Merck、 Labcorp Drug Development、 Mylan、 Sandoz、 Sanofi Pharmaceuticals、 AdvaCare Pharma、 EUROAPI、 Lupin Ltd、 Olon S.p.A、 CKD Bio Corporation、 Fermic、 Sichuan Long March Pharmaceutical Co. Ltd.、 Novartis Pharmaceuticals Corporation、 Hanways Chempharm Co., Limited、 Otto Brandes、 Arudavis Labs、 Zhengzhou Minzhong Pharmaceutical Co., Ltd、 Lannett、 Acme Pharmaceuticals、 Macleods Pharmaceuticals Ltd.
...

This report aims to provide a comprehensive presentation of the global market for Rifamycin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rifamycin. This report contains market size and forecasts of Rifamycin in global, including the following market information:
Global Rifamycin Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Rifamycin market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Tablet Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Rifamycin include Merck, Labcorp Drug Development, Mylan, Sandoz, Sanofi Pharmaceuticals, AdvaCare Pharma, EUROAPI, Lupin Ltd and Olon S.p.A, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Rifamycin companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Rifamycin Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Rifamycin Market Segment Percentages, by Type, 2022 (%)
Tablet
Capsule
Global Rifamycin Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Rifamycin Market Segment Percentages, by Application, 2022 (%)
Pharmacy
Hospital
Clinic
Others
Global Rifamycin Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Rifamycin Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Rifamycin revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Rifamycin revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Labcorp Drug Development
Mylan
Sandoz
Sanofi Pharmaceuticals
AdvaCare Pharma
EUROAPI
Lupin Ltd
Olon S.p.A
CKD Bio Corporation
Fermic
Sichuan Long March Pharmaceutical Co. Ltd.
Novartis Pharmaceuticals Corporation
Hanways Chempharm Co., Limited
Otto Brandes
Arudavis Labs
Zhengzhou Minzhong Pharmaceutical Co., Ltd
Lannett
Acme Pharmaceuticals
Macleods Pharmaceuticals Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Rifamycin, market overview.
Chapter 2: Global Rifamycin market size in revenue.
Chapter 3: Detailed analysis of Rifamycin company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Rifamycin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Rifamycin Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Rifamycin Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Rifamycin Overall Market Size
2.1 Global Rifamycin Market Size: 2022 VS 2029
2.2 Global Rifamycin Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Rifamycin Players in Global Market
3.2 Top Global Rifamycin Companies Ranked by Revenue
3.3 Global Rifamycin Revenue by Companies
3.4 Top 3 and Top 5 Rifamycin Companies in Global Market, by Revenue in 2022
3.5 Global Companies Rifamycin Product Type
3.6 Tier 1, Tier 2 and Tier 3 Rifamycin Players in Global Market
3.6.1 List of Global Tier 1 Rifamycin Companies
3.6.2 List of Global Tier 2 and Tier 3 Rifamycin Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Rifamycin Market Size Markets, 2022 & 2029
4.1.2 Tablet
4.1.3 Capsule
4.2 By Type – Global Rifamycin Revenue & Forecasts
4.2.1 By Type – Global Rifamycin Revenue, 2018-2023
4.2.2 By Type – Global Rifamycin Revenue, 2024-2029
4.2.3 By Type – Global Rifamycin Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Rifamycin Market Size, 2022 & 2029
5.1.2 Pharmacy
5.1.3 Hospital
5.1.4 Clinic
5.1.5 Others
5.2 By Application – Global Rifamycin Revenue & Forecasts
5.2.1 By Application – Global Rifamycin Revenue, 2018-2023
5.2.2 By Application – Global Rifamycin Revenue, 2024-2029
5.2.3 By Application – Global Rifamycin Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Rifamycin Market Size, 2022 & 2029
6.2 By Region – Global Rifamycin Revenue & Forecasts
6.2.1 By Region – Global Rifamycin Revenue, 2018-2023
6.2.2 By Region – Global Rifamycin Revenue, 2024-2029
6.2.3 By Region – Global Rifamycin Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Rifamycin Revenue, 2018-2029
6.3.2 US Rifamycin Market Size, 2018-2029
6.3.3 Canada Rifamycin Market Size, 2018-2029
6.3.4 Mexico Rifamycin Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Rifamycin Revenue, 2018-2029
6.4.2 Germany Rifamycin Market Size, 2018-2029
6.4.3 France Rifamycin Market Size, 2018-2029
6.4.4 U.K. Rifamycin Market Size, 2018-2029
6.4.5 Italy Rifamycin Market Size, 2018-2029
6.4.6 Russia Rifamycin Market Size, 2018-2029
6.4.7 Nordic Countries Rifamycin Market Size, 2018-2029
6.4.8 Benelux Rifamycin Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Rifamycin Revenue, 2018-2029
6.5.2 China Rifamycin Market Size, 2018-2029
6.5.3 Japan Rifamycin Market Size, 2018-2029
6.5.4 South Korea Rifamycin Market Size, 2018-2029
6.5.5 Southeast Asia Rifamycin Market Size, 2018-2029
6.5.6 India Rifamycin Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Rifamycin Revenue, 2018-2029
6.6.2 Brazil Rifamycin Market Size, 2018-2029
6.6.3 Argentina Rifamycin Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Rifamycin Revenue, 2018-2029
6.7.2 Turkey Rifamycin Market Size, 2018-2029
6.7.3 Israel Rifamycin Market Size, 2018-2029
6.7.4 Saudi Arabia Rifamycin Market Size, 2018-2029
6.7.5 UAE Rifamycin Market Size, 2018-2029
7 Rifamycin Companies Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Rifamycin Major Product Offerings
7.1.4 Merck Rifamycin Revenue in Global Market (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 Labcorp Drug Development
7.2.1 Labcorp Drug Development Company Summary
7.2.2 Labcorp Drug Development Business Overview
7.2.3 Labcorp Drug Development Rifamycin Major Product Offerings
7.2.4 Labcorp Drug Development Rifamycin Revenue in Global Market (2018-2023)
7.2.5 Labcorp Drug Development Key News & Latest Developments
7.3 Mylan
7.3.1 Mylan Company Summary
7.3.2 Mylan Business Overview
7.3.3 Mylan Rifamycin Major Product Offerings
7.3.4 Mylan Rifamycin Revenue in Global Market (2018-2023)
7.3.5 Mylan Key News & Latest Developments
7.4 Sandoz
7.4.1 Sandoz Company Summary
7.4.2 Sandoz Business Overview
7.4.3 Sandoz Rifamycin Major Product Offerings
7.4.4 Sandoz Rifamycin Revenue in Global Market (2018-2023)
7.4.5 Sandoz Key News & Latest Developments
7.5 Sanofi Pharmaceuticals
7.5.1 Sanofi Pharmaceuticals Company Summary
7.5.2 Sanofi Pharmaceuticals Business Overview
7.5.3 Sanofi Pharmaceuticals Rifamycin Major Product Offerings
7.5.4 Sanofi Pharmaceuticals Rifamycin Revenue in Global Market (2018-2023)
7.5.5 Sanofi Pharmaceuticals Key News & Latest Developments
7.6 AdvaCare Pharma
7.6.1 AdvaCare Pharma Company Summary
7.6.2 AdvaCare Pharma Business Overview
7.6.3 AdvaCare Pharma Rifamycin Major Product Offerings
7.6.4 AdvaCare Pharma Rifamycin Revenue in Global Market (2018-2023)
7.6.5 AdvaCare Pharma Key News & Latest Developments
7.7 EUROAPI
7.7.1 EUROAPI Company Summary
7.7.2 EUROAPI Business Overview
7.7.3 EUROAPI Rifamycin Major Product Offerings
7.7.4 EUROAPI Rifamycin Revenue in Global Market (2018-2023)
7.7.5 EUROAPI Key News & Latest Developments
7.8 Lupin Ltd
7.8.1 Lupin Ltd Company Summary
7.8.2 Lupin Ltd Business Overview
7.8.3 Lupin Ltd Rifamycin Major Product Offerings
7.8.4 Lupin Ltd Rifamycin Revenue in Global Market (2018-2023)
7.8.5 Lupin Ltd Key News & Latest Developments
7.9 Olon S.p.A
7.9.1 Olon S.p.A Company Summary
7.9.2 Olon S.p.A Business Overview
7.9.3 Olon S.p.A Rifamycin Major Product Offerings
7.9.4 Olon S.p.A Rifamycin Revenue in Global Market (2018-2023)
7.9.5 Olon S.p.A Key News & Latest Developments
7.10 CKD Bio Corporation
7.10.1 CKD Bio Corporation Company Summary
7.10.2 CKD Bio Corporation Business Overview
7.10.3 CKD Bio Corporation Rifamycin Major Product Offerings
7.10.4 CKD Bio Corporation Rifamycin Revenue in Global Market (2018-2023)
7.10.5 CKD Bio Corporation Key News & Latest Developments
7.11 Fermic
7.11.1 Fermic Company Summary
7.11.2 Fermic Business Overview
7.11.3 Fermic Rifamycin Major Product Offerings
7.11.4 Fermic Rifamycin Revenue in Global Market (2018-2023)
7.11.5 Fermic Key News & Latest Developments
7.12 Sichuan Long March Pharmaceutical Co. Ltd.
7.12.1 Sichuan Long March Pharmaceutical Co. Ltd. Company Summary
7.12.2 Sichuan Long March Pharmaceutical Co. Ltd. Business Overview
7.12.3 Sichuan Long March Pharmaceutical Co. Ltd. Rifamycin Major Product Offerings
7.12.4 Sichuan Long March Pharmaceutical Co. Ltd. Rifamycin Revenue in Global Market (2018-2023)
7.12.5 Sichuan Long March Pharmaceutical Co. Ltd. Key News & Latest Developments
7.13 Novartis Pharmaceuticals Corporation
7.13.1 Novartis Pharmaceuticals Corporation Company Summary
7.13.2 Novartis Pharmaceuticals Corporation Business Overview
7.13.3 Novartis Pharmaceuticals Corporation Rifamycin Major Product Offerings
7.13.4 Novartis Pharmaceuticals Corporation Rifamycin Revenue in Global Market (2018-2023)
7.13.5 Novartis Pharmaceuticals Corporation Key News & Latest Developments
7.14 Hanways Chempharm Co., Limited
7.14.1 Hanways Chempharm Co., Limited Company Summary
7.14.2 Hanways Chempharm Co., Limited Business Overview
7.14.3 Hanways Chempharm Co., Limited Rifamycin Major Product Offerings
7.14.4 Hanways Chempharm Co., Limited Rifamycin Revenue in Global Market (2018-2023)
7.14.5 Hanways Chempharm Co., Limited Key News & Latest Developments
7.15 Otto Brandes
7.15.1 Otto Brandes Company Summary
7.15.2 Otto Brandes Business Overview
7.15.3 Otto Brandes Rifamycin Major Product Offerings
7.15.4 Otto Brandes Rifamycin Revenue in Global Market (2018-2023)
7.15.5 Otto Brandes Key News & Latest Developments
7.16 Arudavis Labs
7.16.1 Arudavis Labs Company Summary
7.16.2 Arudavis Labs Business Overview
7.16.3 Arudavis Labs Rifamycin Major Product Offerings
7.16.4 Arudavis Labs Rifamycin Revenue in Global Market (2018-2023)
7.16.5 Arudavis Labs Key News & Latest Developments
7.17 Zhengzhou Minzhong Pharmaceutical Co., Ltd
7.17.1 Zhengzhou Minzhong Pharmaceutical Co., Ltd Company Summary
7.17.2 Zhengzhou Minzhong Pharmaceutical Co., Ltd Business Overview
7.17.3 Zhengzhou Minzhong Pharmaceutical Co., Ltd Rifamycin Major Product Offerings
7.17.4 Zhengzhou Minzhong Pharmaceutical Co., Ltd Rifamycin Revenue in Global Market (2018-2023)
7.17.5 Zhengzhou Minzhong Pharmaceutical Co., Ltd Key News & Latest Developments
7.18 Lannett
7.18.1 Lannett Company Summary
7.18.2 Lannett Business Overview
7.18.3 Lannett Rifamycin Major Product Offerings
7.18.4 Lannett Rifamycin Revenue in Global Market (2018-2023)
7.18.5 Lannett Key News & Latest Developments
7.19 Acme Pharmaceuticals
7.19.1 Acme Pharmaceuticals Company Summary
7.19.2 Acme Pharmaceuticals Business Overview
7.19.3 Acme Pharmaceuticals Rifamycin Major Product Offerings
7.19.4 Acme Pharmaceuticals Rifamycin Revenue in Global Market (2018-2023)
7.19.5 Acme Pharmaceuticals Key News & Latest Developments
7.20 Macleods Pharmaceuticals Ltd.
7.20.1 Macleods Pharmaceuticals Ltd. Company Summary
7.20.2 Macleods Pharmaceuticals Ltd. Business Overview
7.20.3 Macleods Pharmaceuticals Ltd. Rifamycin Major Product Offerings
7.20.4 Macleods Pharmaceuticals Ltd. Rifamycin Revenue in Global Market (2018-2023)
7.20.5 Macleods Pharmaceuticals Ltd. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Rifamycin Market Opportunities & Trends in Global Market
Table 2. Rifamycin Market Drivers in Global Market
Table 3. Rifamycin Market Restraints in Global Market
Table 4. Key Players of Rifamycin in Global Market
Table 5. Top Rifamycin Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Rifamycin Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Rifamycin Revenue Share by Companies, 2018-2023
Table 8. Global Companies Rifamycin Product Type
Table 9. List of Global Tier 1 Rifamycin Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Rifamycin Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Rifamycin Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Rifamycin Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Rifamycin Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Rifamycin Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Rifamycin Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Rifamycin Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Rifamycin Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Rifamycin Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Rifamycin Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Rifamycin Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Rifamycin Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Rifamycin Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Rifamycin Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Rifamycin Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Rifamycin Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Rifamycin Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Rifamycin Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Rifamycin Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Rifamycin Revenue, (US$, Mn), 2024-2029
Table 30. Merck Company Summary
Table 31. Merck Rifamycin Product Offerings
Table 32. Merck Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 33. Merck Key News & Latest Developments
Table 34. Labcorp Drug Development Company Summary
Table 35. Labcorp Drug Development Rifamycin Product Offerings
Table 36. Labcorp Drug Development Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 37. Labcorp Drug Development Key News & Latest Developments
Table 38. Mylan Company Summary
Table 39. Mylan Rifamycin Product Offerings
Table 40. Mylan Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 41. Mylan Key News & Latest Developments
Table 42. Sandoz Company Summary
Table 43. Sandoz Rifamycin Product Offerings
Table 44. Sandoz Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 45. Sandoz Key News & Latest Developments
Table 46. Sanofi Pharmaceuticals Company Summary
Table 47. Sanofi Pharmaceuticals Rifamycin Product Offerings
Table 48. Sanofi Pharmaceuticals Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 49. Sanofi Pharmaceuticals Key News & Latest Developments
Table 50. AdvaCare Pharma Company Summary
Table 51. AdvaCare Pharma Rifamycin Product Offerings
Table 52. AdvaCare Pharma Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 53. AdvaCare Pharma Key News & Latest Developments
Table 54. EUROAPI Company Summary
Table 55. EUROAPI Rifamycin Product Offerings
Table 56. EUROAPI Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 57. EUROAPI Key News & Latest Developments
Table 58. Lupin Ltd Company Summary
Table 59. Lupin Ltd Rifamycin Product Offerings
Table 60. Lupin Ltd Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 61. Lupin Ltd Key News & Latest Developments
Table 62. Olon S.p.A Company Summary
Table 63. Olon S.p.A Rifamycin Product Offerings
Table 64. Olon S.p.A Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 65. Olon S.p.A Key News & Latest Developments
Table 66. CKD Bio Corporation Company Summary
Table 67. CKD Bio Corporation Rifamycin Product Offerings
Table 68. CKD Bio Corporation Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 69. CKD Bio Corporation Key News & Latest Developments
Table 70. Fermic Company Summary
Table 71. Fermic Rifamycin Product Offerings
Table 72. Fermic Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 73. Fermic Key News & Latest Developments
Table 74. Sichuan Long March Pharmaceutical Co. Ltd. Company Summary
Table 75. Sichuan Long March Pharmaceutical Co. Ltd. Rifamycin Product Offerings
Table 76. Sichuan Long March Pharmaceutical Co. Ltd. Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 77. Sichuan Long March Pharmaceutical Co. Ltd. Key News & Latest Developments
Table 78. Novartis Pharmaceuticals Corporation Company Summary
Table 79. Novartis Pharmaceuticals Corporation Rifamycin Product Offerings
Table 80. Novartis Pharmaceuticals Corporation Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 81. Novartis Pharmaceuticals Corporation Key News & Latest Developments
Table 82. Hanways Chempharm Co., Limited Company Summary
Table 83. Hanways Chempharm Co., Limited Rifamycin Product Offerings
Table 84. Hanways Chempharm Co., Limited Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 85. Hanways Chempharm Co., Limited Key News & Latest Developments
Table 86. Otto Brandes Company Summary
Table 87. Otto Brandes Rifamycin Product Offerings
Table 88. Otto Brandes Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 89. Otto Brandes Key News & Latest Developments
Table 90. Arudavis Labs Company Summary
Table 91. Arudavis Labs Rifamycin Product Offerings
Table 92. Arudavis Labs Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 93. Arudavis Labs Key News & Latest Developments
Table 94. Zhengzhou Minzhong Pharmaceutical Co., Ltd Company Summary
Table 95. Zhengzhou Minzhong Pharmaceutical Co., Ltd Rifamycin Product Offerings
Table 96. Zhengzhou Minzhong Pharmaceutical Co., Ltd Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 97. Zhengzhou Minzhong Pharmaceutical Co., Ltd Key News & Latest Developments
Table 98. Lannett Company Summary
Table 99. Lannett Rifamycin Product Offerings
Table 100. Lannett Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 101. Lannett Key News & Latest Developments
Table 102. Acme Pharmaceuticals Company Summary
Table 103. Acme Pharmaceuticals Rifamycin Product Offerings
Table 104. Acme Pharmaceuticals Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 105. Acme Pharmaceuticals Key News & Latest Developments
Table 106. Macleods Pharmaceuticals Ltd. Company Summary
Table 107. Macleods Pharmaceuticals Ltd. Rifamycin Product Offerings
Table 108. Macleods Pharmaceuticals Ltd. Rifamycin Revenue (US$, Mn) & (2018-2023)
Table 109. Macleods Pharmaceuticals Ltd. Key News & Latest Developments
List of Figures
Figure 1. Rifamycin Segment by Type in 2022
Figure 2. Rifamycin Segment by Application in 2022
Figure 3. Global Rifamycin Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Rifamycin Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Rifamycin Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Rifamycin Revenue in 2022
Figure 8. By Type - Global Rifamycin Revenue Market Share, 2018-2029
Figure 9. By Application - Global Rifamycin Revenue Market Share, 2018-2029
Figure 10. By Type - Global Rifamycin Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Rifamycin Revenue Market Share, 2018-2029
Figure 12. By Application - Global Rifamycin Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Rifamycin Revenue Market Share, 2018-2029
Figure 14. By Region - Global Rifamycin Revenue Market Share, 2018-2029
Figure 15. By Country - North America Rifamycin Revenue Market Share, 2018-2029
Figure 16. US Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Rifamycin Revenue Market Share, 2018-2029
Figure 20. Germany Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 21. France Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Rifamycin Revenue Market Share, 2018-2029
Figure 28. China Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 32. India Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Rifamycin Revenue Market Share, 2018-2029
Figure 34. Brazil Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Rifamycin Revenue Market Share, 2018-2029
Figure 37. Turkey Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Rifamycin Revenue, (US$, Mn), 2018-2029
Figure 41. Merck Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Labcorp Drug Development Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Mylan Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Sandoz Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Sanofi Pharmaceuticals Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. AdvaCare Pharma Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. EUROAPI Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Lupin Ltd Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Olon S.p.A Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. CKD Bio Corporation Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Fermic Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Sichuan Long March Pharmaceutical Co. Ltd. Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Novartis Pharmaceuticals Corporation Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Hanways Chempharm Co., Limited Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Otto Brandes Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Arudavis Labs Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Zhengzhou Minzhong Pharmaceutical Co., Ltd Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Lannett Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. Acme Pharmaceuticals Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 60. Macleods Pharmaceuticals Ltd. Rifamycin Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



★調査レポート[世界のリファマイシン市場予測2023-2029：タブレット、カプセル] (コード：MMG23LY8640)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のリファマイシン市場予測2023-2029：タブレット、カプセル]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のイブルチニブBTK阻害剤市場予測2023-2029：タブレット、カプセル
  • 世界のヘアサプリメント市場2022年：カプセル、ピル、タブレット
  • 世界の店頭販売（OTC）鎮痛薬市場2022年：タブレット、カプセル、その他
  • 世界の尿検査用ストリップ＆錠剤市場予測2023-2029：ストリップ、タブレット
  • 世界のプロゲステロン薬市場予測2023-2029：カプセル、錠剤、その他

    • ◆H&Iグローバルリサーチのお客様（例）◆